KYMR Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.…
Industry Peers
BiotechnologyKey Statistics
About Kymera Therapeutics (NASDAQ: KYMR)
›
Kymera Therapeutics (NASDAQ: KYMR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 285 employees.
The shares were at 119.39 USD on 19 November 2026, up 95.7% over 52 weeks. Its 52-week range is 56.75 USD to 142.92 USD: the price is 16.5% below the high and 110.4% above the low.
Its market capitalisation is 10.19B USD.
Kymera Therapeutics reports return on equity of -19.7% and an operating margin of -396.0%.
It holds more cash than debt, a net cash position of 894.62M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 23 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 145.22 USD is 21.6% above the current price. The next earnings report is expected on 25 February 2027.